IQVIA (NYSE:IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company leverages artificial intelligence, real-world data and extensive domain expertise to help biopharmaceutical, biotechnology and medical device companies accelerate clinical development and improve commercialization outcomes. Its offerings span the full product life cycle, from early‐stage research to post‐approval safety and market access strategies.
The firm’s core services include clinical development and operations, regulatory consulting, real‐world evidence generation, and commercial analytics. IQVIA’s clinical research capabilities encompass trial design, site management, patient recruitment and data management, while its technology platforms integrate data warehousing, advanced analytics and machine learning to deliver actionable insights. The company also provides consulting services focused on market access, pricing and health economics to support launch and reimbursement strategies.
IQVIA was formed in May 2016 through the combination of IMS Health and Quintiles, two established leaders in healthcare information and contract research, respectively. Headquartered in Durham, North Carolina, IQVIA has grown rapidly by expanding its data resources and investing in technology-driven solutions. Under the leadership of Chief Executive Officer Ari Bousbib, the company has emphasized innovation in real-world data and artificial intelligence to address evolving industry challenges.
Operating in more than 100 countries, IQVIA serves a diverse client base that includes pharmaceutical and biotechnology firms, medical device manufacturers, academic institutions, government agencies and payers. Its global footprint and integrated service model enable cross‐border collaboration and the delivery of consistent solutions across multiple therapeutic areas. By combining extensive data assets with advanced analytics capabilities, IQVIA aims to help its clients bring new therapies to market more efficiently and improve patient outcomes worldwide.
